Charles River Laboratories International, Inc.
CRL
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $13.9B
$288.50
▼ -1.65%
P/E
-59.48
Mkt Cap
$13.9B
52-Wk Range
$144.26–$303.31
52-Week Range
$144.26 - $303.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 78.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive end-to-end research services
- Extensive global laboratory network
- Deep scientific expertise
- Established relationships with major pharmaceutical companies
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Increasing pharmaceutical R&D spending
Value
Fairly valued vs Life Sciences Tools peers
Momentum
Hot
+54.7% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $3.02 vs $2.77 consensus (+9.0% surprise). Revenue of $1.0B vs $977.2M expected (+2.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+9.0%
Revenue trend · last 8Q
—
-1%
-3%
+1%
-0%
-1%
+1%
-3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.0B
$1.0B
$984.2M
$1.0B
$1.0B
$994.2M
$995.8M
$1.0B
Margins · last 8Q
Gross
36.2%
Operating
11.9%
Profit
-0.1%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Aug 7, 2026
vs Industry
How CRL stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related